<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4958">
  <stage>Registered</stage>
  <submitdate>10/12/2014</submitdate>
  <approvaldate>10/12/2014</approvaldate>
  <nctid>NCT02316106</nctid>
  <trial_identification>
    <studytitle>A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma</studytitle>
    <scientifictitle>A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>54767414SMM2001</secondaryid>
    <secondaryid>CR106449</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Multiple Myeloma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - daratumumab
Treatment: drugs - daratumumab
Treatment: drugs - daratumumab

Experimental: Arm A (Long Intense) - 

Experimental: Arm B (Intermediate) - 

Experimental: Arm C (Short Intense) - 


Treatment: drugs: daratumumab
16 mg/kg administered by intravenous (IV) infusion once every week in Cycle 1, every other week in Cycle 2 and Cycle 3, every 4 weeks in Cycle 4 to Cycle 7, and from Cycle 8 to Cycle 20 on Day 1 of each cycle. Treatment cycles are 8 weeks in length.

Treatment: drugs: daratumumab
16 mg/kg administered by IV infusion once every week in Cycle 1, and then on Day 1 of each cycle from Cycle 2 to Cycle 20. Treatment cycles are 8 weeks in length.

Treatment: drugs: daratumumab
16 mg/kg administered by IV infusion once every week in Cycle 1 only. Treatment cycles are 8 weeks in length.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The percentage of participants who achieve a complete response (CR) - CR, defined having negative immunofixation on the serum and urine, and &lt;5% plasma cells (PCs) in bone marrow.</outcome>
      <timepoint>Up to approximately 24 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>The percentage of participants that have an event (disease progression or death) per patient-year</outcome>
      <timepoint>Up to approximately 30 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The percentage of participants who are minimal residual disease (MRD) negative</outcome>
      <timepoint>Up to 5.5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to next treatment (TNT) - TNT, defined as the time from the date of randomization to the date of the first subsequent multiple myeloma treatment.</outcome>
      <timepoint>Up to 5.5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The percentage of participants who achieve a Complete Response (CR) or a Partial Response (PR) - See definition of CR above. PR, defined as =50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by =90% or to &lt;200 mg/24 hours.</outcome>
      <timepoint>Up to 5.5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The median time of progression free survival (PFS) - PFS, defined as the time from the date of randomization to the date of initial documented disease progression (PD) or date of death, whichever occurs first.</outcome>
      <timepoint>Up to 5.5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The percentage of participants with symptomatic multiple myeloma</outcome>
      <timepoint>Up to 5.5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Response to first subsequent multiple myeloma treatment</outcome>
      <timepoint>Up to 5.5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival rate</outcome>
      <timepoint>Up to 5.5 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Diagnosis of smoldering multiple myeloma (SMM) for less than 5 years

          -  Have a confirmed diagnosis of intermediate or high-risk SMM, and an Eastern
             Cooperative Oncology Group (ECOG) performance status score of 0 or 1.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>99</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Active multiple myeloma,requiring treatment as defined by the study protocol

          -  Primary systemic AL (immunoglobulin light chain) amyloidosis

          -  Prior or concurrent exposure to any of the following: approved or investigational
             treatments for SMM or/and multiple myeloma, daratumumab or other anti CD-38 therapies,
             treatment with corticosteroids with a dose greater than (&gt;) 10 milligram (mg)
             prednisone per day or equivalent and bone-protecting agents (eg, bisphosphonates,
             denosumab) or are only allowed if given in a stable dose and for a nonmalignant
             condition, or received an investigational drug (including investigational vaccines) or
             used an invasive investigational medical device within 4 weeks before Cycle 1, Day 1

          -  History of malignancy (other than SMM) within 3 years before the date of
             randomization, except for the following if treated and not active: basal cell or
             nonmetastatic squamous cell carcinoma of the skin, cervical carcinoma in situ, ductal
             carcinoma in situ of breast, or International Federation of Gynecology and Obstetrics
             (FIGO) Stage 1 carcinoma of the cervix

          -  Known chronic obstructive pulmonary disease (COPD) OR moderate or severe persistent
             asthma within the past 2 years

          -  Any concurrent medical or psychiatric condition or disease (eg, autoimmune disease,
             active systemic disease, myelodysplasia) that is likely to interfere with the study
             procedures or results, or that in the opinion of the investigator, would constitute a
             hazard for participating in this study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>20/05/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>126</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>27/11/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Box Hill</hospital>
    <hospital> - Concord</hospital>
    <hospital> - Melbourne</hospital>
    <hospital> - Woodville South</hospital>
    <postcode> - Box Hill</postcode>
    <postcode> - Concord</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Woodville South</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Hradec Kralove</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pierre Benite</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rennes Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Chemnitz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>München</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Tuebingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Würzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Petah Tikva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Nizhny Novgorod</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Petrozavodsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Ryazan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St-Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Ankara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Antalya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Izmir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Samsun</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cardiff</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Nottingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Southampton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Surrey</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Janssen Research &amp; Development, LLC</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate three daratumumab dose schedules in participants
      with Smoldering Multiple Myeloma.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02316106</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Janssen Research &amp; Development, LLC Clinical Trial</name>
      <address>Janssen Research &amp; Development, LLC</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>